Latest stories on ARQT
Stock Market Today: Indexes Turn Tail After Fed Holds Rates Steady; STX, SNOW, ARQT In Focus
Investors.com48 · neutralgeneral
Arcutis: Intense Competition, Costs, Slow Growth Merit Downgrade To Hold
Seeking Alpha38 · neutralanalyst
Arcutis Biotherapeutics Adds Veteran Director to Board
TipRanks56 · neutralgeneral
Arcutis Biotherapeutics, Inc. (ARQT) files 8-K
SEC 8-K50 · neutralgeneral
Arcutis Expands Board of Directors with Appointment of Chris Peetz | ARQT Stock News
StockTitan56 · neutralgeneral
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
Investors.com63 · neutralproduct/pr
Arcutis gets FDA review for Zoryve 0.05% label expansion
Seeking Alpha67 · bullishproduct/pr
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News
StockTitan50 · neutralgeneral
Arcutis Biotherapeutics' Psoriasis Cream Gets FDA Approval for Young Children
Morningstar73 · bullishproduct/pr
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
The Motley Fool42 · neutralgeneral
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
Yahoo Finance73 · bullishproduct/pr
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha55 · neutralgeneral
Arcutis Stockholders Approve Proposals at 2026 Meeting
TipRanks50 · neutralgeneral
Arcutis Biotherapeutics, Inc. (ARQT) files 8-K
SEC 8-K50 · neutralgeneral
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News
StockTitan50 · neutralgeneral
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference | ARQT Stock News
StockTitan55 · neutralgeneral
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound
Seeking Alpha63 · neutralproduct/pr